https://orcid.org/0000-0002-6503-2850
![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Background: The current work was designed to estimate the cost–effectiveness of trifluridine/tipiracil (T/T) versus best supportive care (BSC) for patients with advanced stage or metastatic gastroesophageal cancer (mGC) from a UK perspective. Materials & methods: A partitioned survival analysis was undertaken using data from the phase III TAGS trial. A jointly fitted lognormal model was selected for overall survival and individual generalized gamma models were chosen for progression-free survival and time-to-treatment-discontinuation. The primary outcome was the cost per quality-adjusted life year (QALY) gained. Sensitivity analyses were undertaken to investigate uncertainty. Results: Compared with BSC, T/T was associated with a cost per QALY gained of £37,907. Conclusion: T/T provides a cost-effective treatment option for mGC in the UK setting.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2022-0662
Author contributions
L Hamerton, E Hook and A Bullement developed the original cost–effectiveness model used to inform this study and contributed to the drafting of the original manuscript. K Gomes provided data and information concerning clinical aspects of the model and manuscript, and contributed to the drafting of the manuscript. R Fougeray provided input to the statistical analyses presented in this study and the original analyses of the TAGS study data used to populate the model. M Vargas Gomes and O Hauch provided input to the final cost-effectiveness model analyses presented in the manuscript and contributed to the writing of the manuscript. All authors reviewed the draft versions of the manuscript and approved the final version ahead of submission.
Financial & competing interests disclosure
This work was funded by Les Laboratoires Servier, the manufacturer and marketing authorization holder for trifluridine/tipiracil (Lonsurf®). L Hamerton, K Gomes, R Fougeray, M Vargas Gomes and O Hauch are employees of Servier and/or its subsidiaries. E S Hook and A Bullement are employees of Delta Hat Ltd, an independent consultancy that received fees from Servier Affaires Medical for the development of the cost-effectiveness model. Medical writing and editorial support were provided by A Bullement and E S Hook of Delta Hat Ltd, and were funded by Servier Affaires Medical. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Data sharing statement
The authors certify that this manuscript reports the secondary analysis of clinical trial data that have been shared with them, and that the use of this shared data is in accordance with the terms (if any) agreed upon their receipt. The source of this data is: TAGS study, NCT02500043, Taiho Oncology, Inc.